Prevention of Venous Thromboembolism

Stratton, Mark A.; Anderson, Fredrick A.; Bussey, Henry I.; Caprini, Joseph A.; Comerota, Anthony J.; Haines, Stuart T.; Hawkins, David; O’Connell, Mary Beth; Smith, Richard C.; Stringer, Kathleen A.

doi:10.1001/archinte.160.3.334

Cited by 133 publications

(21 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The earlier data along with our findings suggest that the in-hospital mortality for acute PE has decreased in both sexes, but to a lesser degree for women during 2003-2011. The overall decline in mortality in the whole cohort is consistent with previous data and likely represents improved diagnosis and treatment capability 12,13 . The explanation for the lag in the mortality improvement among women is not clear, but findings from this study might help elucidate potential contributors to the disparity.…”

Section: Discussionsupporting

confidence: 88%

Gender Disparities in Outcomes and Resource Utilization for Acute Pulmonary Embolism Hospitalizations in the United States

Agarwal

Clark

Sud

et al. 2015

The American Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Gender Disparities in Outcomes and Resource Utilization for Acute Pulmonary Embolism Hospitalizations in the United States

Agarwal

Clark

Sud

et al. 2015

The American Journal of Cardiology

View full text Add to dashboard Cite

“…However, practice audits continue to demonstrate that thromboprophylaxis is underutilized [62][63][64][65] and further, while existing thromboprophylaxis regimens are effective, they do not eliminate the risk of VTE [61]. Unfortunately, nearly 50% of VTE events occur unpredictably, therefore are not preventable with thromboprophylaxis [62,66].…”

Section: Preventing Ptsmentioning

confidence: 99%

The Post-thrombotic Syndrome: The Forgotten Morbidity of Deep Venous Thrombosis

Kahn

2006

J Thromb Thrombolysis

View full text Add to dashboard Cite

The postthrombotic syndrome (PTS) is the most common complication of deep venous thrombosis (DVT) yet has received little attention from clinicians and researchers. Clinically, PTS is characterized by chronic pain, swelling, heaviness and other signs in the affected limb. In severe cases, venous ulcers may develop. PTS is burdensome and costly to patients and society because of its high prevalence, severity and chronicity. Preventing DVT with the use of effective thromboprophylaxis in high-risk patients and settings and minimizing the risk of ipsilateral DVT recurrence are likely to reduce the frequency of PTS. Compression stockings worn daily after DVT appear to reduce the incidence and severity of PTS but questions regarding their use and effectiveness remain. Future research should focus on identifying patients at high risk for PTS, assessing the role of thrombolysis in preventing PTS and evaluating the optimal use of compression stockings in preventing and treating PTS. In addition, new therapies to treat PTS should be sought and evaluated.

show abstract

“…During the last 10 years, many evidence-based guidelines for orthopedic thromboprophylaxis have been published [26][27][28][29][30][31][32]. Owing to the inconsistent study design of many trials, it is difficult to conclude which strategy fits best with a safety balance between major bleeding disorders and efficacy to prevent DVT and PE.…”

Section: Expert Commentary and Five-year Viewmentioning

confidence: 99%

Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban

Ivanovic

Beinema

Brouwers³

et al. 2007

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Low-molecular weight heparins are standard therapy for patients requiring thromboprophylaxis and, therefore, we compare these with the other agents: vitamin K antagonists, fondaparinux and the direct oral inhibitors (thrombin or factor Xa inhibitors). The most evidence on the cost-effectiveness and efficacy is available for the low-molecular weight heparins and fondaparinux. Their major limitation is that they require parenteral administration. Only fondaparinux has undergone an extensive pharmacoeconomic evaluation. The direct thrombin inhibitors and direct factor Xa inhibitors are possibly the drugs of the future, but it must be borne in mind that they are still in Phase III clinical trials and, therefore,their safety and efficacy profile is not completely understood, neither are the pharmacoeconomic aspects.

show abstract

Prevention of Venous Thromboembolism

Cited by 133 publications

References 11 publications

Gender Disparities in Outcomes and Resource Utilization for Acute Pulmonary Embolism Hospitalizations in the United States

Gender Disparities in Outcomes and Resource Utilization for Acute Pulmonary Embolism Hospitalizations in the United States

The Post-thrombotic Syndrome: The Forgotten Morbidity of Deep Venous Thrombosis

Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban

Contact Info

Product

Resources

About